An evaluation is requested for a 68-year-old man who has developed severe anxiety, worseni… — USMLE Step 2 CK

An evaluation is requested for a 68-year-old man who has developed severe anxiety, worsening palpitations, and a $4.5\text{-kg}$ ( $10\text{-lb}$ ) unintentional weight loss over the past four weeks. He has a complex cardiovascular history including ischemic cardiomyopathy and recurrent ventricular tachycardia, which is currently managed with metoprolol, lisinopril, aspirin, and amiodarone. The amiodarone was initiated two years ago. Vital signs show a pulse of $112\text{/min}$ with an irregular rhythm, and blood pressure is $138/82\text{ mmHg}$ . Physical examination reveals hyperreflexia, warm and moist skin, and a bilateral fine hand tremor. A non-tender, symmetrically enlarged thyroid gland is appreciated on palpation.

Recent laboratory results are as follows:

Laboratory Test	Result	Reference Range
Thyroid-stimulating hormone (TSH)	$0.02\text{ mIU/L}$	$0.4-4.0\text{ mIU/L}$
Free thyroxine (T4)	$3.8\text{ ng/dL}$	$0.9-1.7\text{ ng/dL}$
Total triiodothyronine (T3)	$210\text{ ng/dL}$	$80-200\text{ ng/dL}$

Which of the following is the most appropriate next step in the evaluation of this patient's current condition?

Color flow Doppler ultrasonography of the thyroidCevap
B
Radioactive iodine uptake (RAIU) scan
C
Immediate discontinuation of amiodarone
D
Initiation of methimazole therapy
E
Measurement of serum thyroglobulin concentration

Cevap

Color flow Doppler ultrasonography of the thyroid

The correct response is color flow Doppler ultrasonography of the thyroid. This patient's suppressed TSH and elevated thyroid hormones confirm thyrotoxicosis, and his medication history strongly points to amiodarone-induced thyrotoxicosis (AIT). Amiodarone can cause thyrotoxicosis through two distinct mechanisms. Type 1 AIT occurs in patients with underlying thyroid pathology (e.g., latent Graves disease or multinodular goiter) where the massive iodine load in amiodarone fuels excessive hormone synthesis (Jod-Basedow phenomenon). Type 2 AIT is a destructive thyroiditis caused by the direct toxic effect of amiodarone on follicular cells, leading to the release of preformed hormone. Differentiating these two is absolutely critical because management differs significantly: Type 1 requires synthesis inhibitors (methimazole), whereas Type 2 requires anti-inflammatory therapy (glucocorticoids). Because the massive iodine load of amiodarone renders standard radioactive iodine uptake (RAIU) scans useless (uptake will be suppressed in both types), color flow Doppler ultrasonography is the preferred initial diagnostic test. Type 1 AIT typically shows normal or increased vascularity, while Type 2 AIT demonstrates decreased or absent vascularity.

Adım Adım Çözüm

Analyze the patient's clinical presentation and laboratory findings.

The patient has signs of thyrotoxicosis (tremor, weight loss, palpitations, suppressed TSH, elevated Free T4 and T3) in the setting of chronic amiodarone use.

Establishing the biochemical diagnosis of thyrotoxicosis and identifying the likely offending pharmacologic agent is the necessary first step.

Recall the distinct pathophysiology of amiodarone-induced thyrotoxicosis (AIT).

AIT presents in two forms: Type 1 (hyperthyroidism due to underlying autonomous tissue exposed to iodine load) and Type 2 (destructive thyroiditis due to direct drug toxicity).

Differentiation is critical because the treatments are diametrically opposed: thionamides for Type 1 and glucocorticoids for Type 2.

Select the appropriate diagnostic modality to differentiate the subtypes.

Color flow Doppler ultrasonography is selected.

Standard nuclear medicine scans (RAIU) are invalid due to amiodarone's massive iodine content. Doppler ultrasound circumvents this by structurally evaluating blood flow (increased in Type 1, decreased in Type 2).

Anahtar Kavram

Differentiation of Amiodarone-Induced Thyrotoxicosis Subtypes

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru